Characteristic | Budesonide (N = 48) | Placebo (N = 43) | p Value |
---|---|---|---|
Male sex - no. (%) | 30 (62.5) | 29 (67.4) | 0.662 |
0.662 Median age (yrs) - Mean (SD) | 53.1 + 12.2 | 52.0 + 12.9 | 0.660* |
Duration of disease (mths) -Mean (SD) | 23.4 + 33.4 | 15.4 + 15.4 | 0.139* |
Complete remission pre-SZT - no. (%) | 18 (38.3) | 17 (40.5) | 0.834 |
Basic disease - no. (%) | Â | Â | 0.179 |
Myelodysplastic syndrome - MDS | 5 (10.6) | 7 (16.3) | Â |
Acute myeloid leucemia - AML | 19 (40.4) | 14 (32.6) | Â |
Acute lymphoblastic leucemia - ALL | 7 (14.6) | 4 (9.3) | Â |
Chronic myeloid leucemia - CML | 1 (2.1) | Â | Â |
Chronic lymphocytic leucemia - CLL | 1 (2.1) | 2 (4.7) | Â |
Non Hodgkin lymphoma - NHL /M. Hodgkin | 6 (12.8) | 3 (7.0) | Â |
Multiple myeloma | 3 (6.4) | 11 (25.6) | Â |
Others | 5 (10.6) | 2 (4.7) | Â |
Chemotherapeutic conditioning - no. (%) | 44 (91.7) | 36 (83.7) | 0.246 |
Total body irradiation -TBI - no. (%) | 27 (56.3) | 22 (51.2) | 0.627 |
Dosage reduced induction regimen (%) | 27 (56.3) | 24 (55.8) | 0.967 |
In-vivo T-cell depletion (%) | 29 (60.4) | 26 (60.5) | 0.994 |
Sibling transplant (%) | 17 (35.4) | 15 (34.9) | 0.958 |
CMV-status positive - no. (%) | 31 (64.6) | 32 (74.4) | 0.31 |